Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2020

01-08-2020 | Breast Cancer | Clinical Trial

The effect of 1-day multidisciplinary clinic on breast cancer treatment

Authors: Zohaib Akhtar, Vered Stearns, Paul Cartwright, Amanda L. Blackford, Vishnu Prasath, Catherine Klein, Danijela Jelovac, Fariba Asrari, Mehran Habibi

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Abstract

Purpose

A delay in breast cancer treatment is associated with inferior survival outcomes; however, no clear guidelines exist defining the appropriate time frame from diagnosis to definitive treatment of breast cancer. A multidisciplinary approach for breast cancer treatment can minimize the time from diagnosis to first treatment. We hypothesized single-day multidisciplinary clinic (MDC) may accelerate the time to first treatment on complex breast cancer cases at our institution.

Methods

We identified patients who were treated at Johns Hopkins for stage II or III breast cancer, who were at least 18 years of age, and were seen in a new single-day MDC with coordination between two or three specialties or by specialists from varying disciplines on different days (IDC). Patients who initiated treatment between May 2015 (initiation of MDC clinic) and December 2017 were included in our study.

Results

A total of 296 patient records were reviewed independently. The mean (SD) patient age was 55 (13) years. The median time to first neoadjuvant chemotherapy (NACT) was significantly reduced for patients seen in the MDC (12.7 days), compared to those seen at the IDC (24.4 days, logrank p < 0.001). The median time to definitive surgery was similar between groups (31 and 32 days for the MDC and IDC cohorts, respectively).

Conclusions

A single-day MDC visit is associated with a reduced time from diagnosis to NACT. Further studies are needed to determine if a shorter interval can improve the management and the outcome of complex breast cancer cases.
Literature
1.
go back to reference Pawlik TM et al (2008) Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 15:2081–2088CrossRefPubMedPubMedCentral Pawlik TM et al (2008) Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 15:2081–2088CrossRefPubMedPubMedCentral
2.
go back to reference Gabel M, Hilton NE, Nathanson SD (1997) Multidisciplinary breast cancer clinics: do they work? Cancer 79:2380–2384CrossRefPubMed Gabel M, Hilton NE, Nathanson SD (1997) Multidisciplinary breast cancer clinics: do they work? Cancer 79:2380–2384CrossRefPubMed
3.
go back to reference Saini KS et al (2012) Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol 23:853–859CrossRefPubMed Saini KS et al (2012) Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol 23:853–859CrossRefPubMed
4.
go back to reference Zhang J et al (2013) Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol 20:e123–e131PubMedPubMedCentral Zhang J et al (2013) Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol 20:e123–e131PubMedPubMedCentral
5.
go back to reference R Core Team (2019) R: a language and environment for statistical computing R Core Team (2019) R: a language and environment for statistical computing
7.
go back to reference Gralow JR et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26(5):814–819CrossRefPubMed Gralow JR et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26(5):814–819CrossRefPubMed
8.
go back to reference Shannon C, Smith I (2003) Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45(1):77–90CrossRefPubMed Shannon C, Smith I (2003) Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45(1):77–90CrossRefPubMed
9.
go back to reference Walter P, Bernhard U, Menger M, Keller HE, Schorlemmer HU, Feifel G (1990) New immunosuppressive agents in experimental allogeneic heart transplantation. Transpl Proc 22(5):2324 Walter P, Bernhard U, Menger M, Keller HE, Schorlemmer HU, Feifel G (1990) New immunosuppressive agents in experimental allogeneic heart transplantation. Transpl Proc 22(5):2324
11.
go back to reference Richard MA et al (1999) Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol 135(3):269–274CrossRefPubMed Richard MA et al (1999) Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol 135(3):269–274CrossRefPubMed
12.
go back to reference Menczer J (2000) Diagnosis and treatment delay in gynecological malignancies. does it affect outcome? Int J Gynecol Cancer 10:89–94CrossRefPubMed Menczer J (2000) Diagnosis and treatment delay in gynecological malignancies. does it affect outcome? Int J Gynecol Cancer 10:89–94CrossRefPubMed
13.
go back to reference Elit LM, O’Leary EM, Pond GR, Seow HY (2014) Impact of wait times on survival for women with uterine cancer. J Clin Oncol 32(1):27–33CrossRefPubMed Elit LM, O’Leary EM, Pond GR, Seow HY (2014) Impact of wait times on survival for women with uterine cancer. J Clin Oncol 32(1):27–33CrossRefPubMed
14.
go back to reference Gobbi PG et al (2013) The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiol 37(2):186–190CrossRefPubMed Gobbi PG et al (2013) The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiol 37(2):186–190CrossRefPubMed
15.
go back to reference Pruitt SL, Harzke AJ, Davidson NO, Schootman M (2013) Do diagnostic and treatment delays for colorectal cancer increase risk of death? Cancer Causes Control 24(5):961–977CrossRefPubMedPubMedCentral Pruitt SL, Harzke AJ, Davidson NO, Schootman M (2013) Do diagnostic and treatment delays for colorectal cancer increase risk of death? Cancer Causes Control 24(5):961–977CrossRefPubMedPubMedCentral
16.
go back to reference Neal RD et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112:S92–S107CrossRefPubMedPubMedCentral Neal RD et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112:S92–S107CrossRefPubMedPubMedCentral
19.
go back to reference Saito AI, Suda M, Sasai K, Jagsi R (2016) Satisfaction of breast cancer patients regarding surgery and radiation therapy: a survey in Japan. Adv Radiat Oncol 1:216–221CrossRefPubMedPubMedCentral Saito AI, Suda M, Sasai K, Jagsi R (2016) Satisfaction of breast cancer patients regarding surgery and radiation therapy: a survey in Japan. Adv Radiat Oncol 1:216–221CrossRefPubMedPubMedCentral
20.
go back to reference Harness JK, Bartlett RH, Saran PA, Bord MA, Noble WC (1987) Developing a comprehensive breast center. Am Surg 53:419–423PubMed Harness JK, Bartlett RH, Saran PA, Bord MA, Noble WC (1987) Developing a comprehensive breast center. Am Surg 53:419–423PubMed
21.
go back to reference Bleiche R et al (2016) Time to surgery and breast cancer survival in the United States. JAMA Oncol 2(3):330–339CrossRef Bleiche R et al (2016) Time to surgery and breast cancer survival in the United States. JAMA Oncol 2(3):330–339CrossRef
22.
go back to reference Lee SH et al (2016) Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine (Baltimore) 95(37):e4874CrossRef Lee SH et al (2016) Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine (Baltimore) 95(37):e4874CrossRef
23.
go back to reference Friedman EL, Kruklitis RJ, Patson BJ, Sopka DM, Weiss MJ (2016) Effectiveness of a thoracic multidisciplinary clinic in the treatment of stage III non-small-cell lung cancer. J Multidiscip Healthc 9:267–274CrossRefPubMedPubMedCentral Friedman EL, Kruklitis RJ, Patson BJ, Sopka DM, Weiss MJ (2016) Effectiveness of a thoracic multidisciplinary clinic in the treatment of stage III non-small-cell lung cancer. J Multidiscip Healthc 9:267–274CrossRefPubMedPubMedCentral
25.
go back to reference Chang JH et al (2001) The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 91(7):1231–1237CrossRefPubMed Chang JH et al (2001) The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 91(7):1231–1237CrossRefPubMed
26.
go back to reference Newman EA et al (2006) Changes in surgical management resulting from case review at a breast cancer multldisciplinary tumor board. Cancer 107:2346–2351CrossRefPubMed Newman EA et al (2006) Changes in surgical management resulting from case review at a breast cancer multldisciplinary tumor board. Cancer 107:2346–2351CrossRefPubMed
Metadata
Title
The effect of 1-day multidisciplinary clinic on breast cancer treatment
Authors
Zohaib Akhtar
Vered Stearns
Paul Cartwright
Amanda L. Blackford
Vishnu Prasath
Catherine Klein
Danijela Jelovac
Fariba Asrari
Mehran Habibi
Publication date
01-08-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05721-3

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine